Longevity World Forum confirms Valencia as its venue in 2019

After the success of its first edition at the end of 2018, it was announced during the closing ceremony of the first Longevity World Forum that a second edition would be held. The organisers of this international congress, a pioneering event in Europe on human longevity, have now confirmed this, specifying that it will take place on 13 and 14 November 2019 at the Palacio de Congresos (Conference Centre) of Valencia, a city that will thus be consolidated as a scientific capital on a global scale.

This decision is the result of the good context currently offered by Valencia, where the academic and scientific ambience, accompanied by innovation and research, present a notable development. Added to this is a growing biotechnology and biomedicine cluster comprising numerous companies and organisations with national and international projection. With all this in mind, the organisers of the Longevity World Forum have once again opted for the city on the river Turia ahead of bids from other European cities to host the event.

Therefore, for the second year running, Valencia will serve as a meeting point for the world scientific community and representatives from academia and industry from different countries, whose work is intimately related to increasing life expectancy and healthy aging. Thus, human longevity will once again be examined from different perspectives, generating multidisciplinary knowledge and showing the latest advances in this field. In short, the organisers of the Longevity World Forum aspire to improve on the good results of its first edition, which boasted over 400 attendees and a programme that included more than 20 first-class speakers. For example, this was the case of Aubrey de Grey, the famous biogerontologist and founder of the American organisation SENS Research Foundation; Ángela Nieto, director of the Developmental Neurobiology Unit of the Neuroscience Institute of Alicante UMH-CSIC; María Blasco, director of the prestigious National Cancer Research Centre (CNIO); José Viña and Federico Pallardó, professors of physiology at the Universitat de València; Lissette Otero, chief medical officer and laboratory director of Life Length; Maria Chatzou, CEO of Lifebit; Manuel Pérez Alonso, professor of genetics at the UV; and Manuel Corpas, founder and CEO of Cambridge Precision Medicine; among other relevant voices.